http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2006527163-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2-0088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-755 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2-0094 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2-0011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-755 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L2-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate | 2003-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2006-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2006527163-A |
| titleOfInvention | Surface treatment of lung SARS disease infection |
| abstract | SARS (Severe Acute Respiratory Syndrome) virus causes global viral pneumonia, is internationally vigilant, mortality is not very low, and it is well known that there is still no effective method for SARS in the medical community. . In medical history since one hundred years, the infection of the lungs has been a disease of visceral tissue, but the present invention explained this misunderstanding of medical interpretation. The reason should be defined on the basis of air, and SARS infection is the first disease of superficial ulcer infection. Based on the above changes in medical interpretation, we have discovered the best way to treat SARS. It is no longer impossible for early-stage SARS-infected persons to be discharged within a few hours after receiving lung lavage treatment in the hospital. SARS virus no longer kills human life, and humans have defeated SARS virus. The surface treatment of SARS infection is a product of a new medical concept, and monomeric oxygen (O 1 ) therapy is at the heart of the surface treatment. A liquid containing a disinfectant, that is, a surface treatment solution of lung monomer oxygenium is injected into the lung. The scientific name of this liquid is liquid perfluorinated chemicals (Perfluoro chemicals. PFC), and the disinfectant is ozone. |
| priorityDate | 2003-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 38.